Hepatocellular carcinoma cell

Hepatocellular carcinoma cells are the malignant epithelial cells that constitute hepatocellular carcinoma, the most common primary liver cancer[9][3]. These cells display significant molecular and biological heterogeneity, with frequent genetic and epigenetic aberrations (e.g., TP53, CTNNB1, FGF19, and TERT mutations; global chromosomal instability; pathway activation involving Wnt/β-catenin, TGF-β, AKT/mTOR, and angiogenesis)[1][2][4]. Clinical and molecular subclassification of HCC is used to understand tumor behavior and guide potential treatment options, but "hepatocellular carcinoma cell" as an entity is not a specific drug target, receptor, or enzyme. Instead, therapeutic strategies often focus on signaling molecules, receptors, or pathways dysregulated in these cells[1][2][4][3].

Other names

HCC cellliver cancer cellhepatoma cell

Multikinase inhibition (e.g., VEGFR, PDGFR, RAF); Cell cycle inhibition (e.g., CDK4/6 inhibitors)[5]; Immunomodulation (immune checkpoint blockade, PD-1/PD-L1 inhibition); Anti-angiogenesis; Other